




ANTIBODIES TO RNA POLYMERASE III



Analysis of autoantibodies against RNA polymerases using immunoaffinity-purified RNA polymerase I, II, and III antigen in an enzyme-linked immunosorbent assay


M Chang¹, R J Wang, D T Yangco, G C Sharp, G R Komatireddy, R W Hoffman



Autoantibodies to RNA polymerases recognize multiple subunits and demonstrate cross-reactivity with RNA polymerase complexes

M Kuwana ¹, Y Okano, J Kaburaki, T A Medsger Jr, T M Wright

RNA POL I **194 + 126**
RNA POL II **240/220 + 145**
RNA POL III **155 + 138**



Immunoprecipitation using

³⁵S-methionine labeled K562 cell extract.

Ceribelli A. Ar.Res.Ther. 2011

Autoantibodies to RNA polymerases recognize multiple subunits and demonstrate cross-reactivity with RNA polymerase complexes

M Kuwana¹, Y Okano, J Kaburaki, T A Medsger Jr, T M Wright

Table 1. Immunoreactivity to individual proteins in RNA polymerase (RNAP) complexes, determined by immunoblotting using 32 anti-RNAP-positive systemic sclerosis patient sera*


RNAP subunit protein	Anti-RNAP I/III/II (n = 5)	Anti-RNAP I/III (n = 23)	Anti-RNAP II alone (n = 4)
240-kd (IIo)	5 (100)†	0	4 (100)
220-kd (IIa)	5 (100)†	0	0
190-kd (Ia)	3 (60)	5 (22)	0
155-kd (IIIa)	5 (100)	23 (100)	0
145-kd (IIc)	2 (40)†	0	0
138-kd (IIIb)	4 (80)	13 (57)	0
126-kd (Ib)	2 (40)	6 (26)	0
84-kd‡	5 (100)	23 (100)	4 (100)
62-kd	5 (100)	21 (91)	0
43-kd	2 (40)	5 (22)	0
34-kd	3 (60)	6 (26)	0
32-kd	3 (60)	12 (52)	0
27-kd	5 (100)	16 (70)	0
23-kd	2 (40)†	0	0
21-kd	4 (80)†	0	0

Line immunoassay using two RNA-Polymerase-III subunits for the sensitive and specific detection of Systemic sclerosis (SSc) specific autoantibodies

**A. Janssen, W. Meyer, T. Scheper, A. Rosemann,
W. Stoecker, and W. Schlumberger**

Institute for Experimental Immunology, affiliated to EUROIMMUN AG, Luebeck, Germany

Congress Of Autoimmunity Slovenia May 2012



RP11

Janssen A.	2010	n=129	RP155	9 (7.0%)	RP155 only : 1
			RP11	7 (5.4%)	RP11 only : 3
			RP155+RP11	10 (7.8%)	
Ott A.	2011	n=136	RP155	17 (12.5%)	
			RP11	14 (10.3%)	
Low A.H.L.	2012	n= 62	RP155	3 (4.4%)	
			RP11	1 (1.5%)	
Villalta D.	2012	n= 210	RP155	12 (5.7%)	RP155 only : 2
			RP11	11 (5.2%)	RP11 only : 1
Bonroy C.	2013	n= 145	RP155	14 (9.7%)	
			RP11	12 (8.3%)	
Wielocz E.	2014	n= 82	RP155	7 (8.0%)	
			RPP11	9 (6.5%)	
Sulau I.	2014	n= 31	RP155	2 (6.5%)	
			RP11	2 (6.5%)	
Alkema W	2021	n= 347	RP155	24 (8.3%)	RP155 only : 7
				23 (6.6%)	RP 11 only : 6

J.luc Charuel Paris	n=78	RP155 + RP11	48 (62%)
		RP155 restreints	18 (23%)
		RP11 restreints	12 (15%)
S. Dubucquoi	n=91	RP 155 + RP11	17 (18.7%)
		RP155 restreints	28 (30.7%)
		RP11 restreints	18 (19.7%)
E. Vinatier	n=49	RP155 + RP11	26 (44.8%)
		RP155 restreints	11 (18.9%)
		RP11 restreints	12 (20.6%)
N.Fabien	n=26	RP155 + RP11	14 (53.8%)
		RP155 restreints	9 (33.6%)
		RP11 restreints	3 (11,5%)
B.Nespola	n=47	PR155 + PR11	37 (78.7%)
		PR155 restreints	4 (8.5 %)
		PR11 restreints	6 (12.7%)

IF HEp2 PR11 monospécifiques

Nicole Fabien

3

- 1. 1280 moucheté + Nucléolaire**
- 2. 320 moucheté**
- 3. négatif**

Sylvain Dubucquoi

18

- 1. 1280 Nucléolaire**
- 2. 1280 Homogène**
- 3. 320 Moucheté**
- 4. 1280 Nucléolaire**
- 5. 320 Nucléolaire**
- 6. 1280 Centromère**
- 7. 1280 Centromère**
- 8. 1280 Moucheté**
- 9-18 Négatif**

J.luc Charuel

12

- 1. non compatible**
- 2. non compatible**
- 3. non compatible**
- 4. non compatible**

PR11 monospécifiques

Nicole Fabien

- 1. Sclérodermie S. Cutanée Limitée**
- 2. PR + Raynaud**
- 3. Raynaud**

Benoit Nespola

- 1. Virose**
- 2. Drépanocytose**
- 3. Sharp**
- 4. Sclérodermie Systémique**
- 5. Sclérodermie Systémique**
- 6. Sclérodermie Systémique**